MICHELLE Trial 2021 (Rivaroxaban in COVID-19)

 The trial's purpose was to compare rivaroxaban to placebo in patients discharged from the hospital with coronavirus disease 2019 (COVID-19) infection.



Design of the Study


Participants who were discharged after being infected with COVID-19 were randomly assigned to receive rivaroxaban 10 mg daily (n = 160) or a placebo (n = 160).


The total number of enrollees: 320.

Follow-up period: 35 days

The average patient age was 58 years.

39% of the population was female.


Criteria for inclusion:


  1. More than the age of 18
  2. COVID-19 infection required hospitalization for at least three days.
  3. Thromboprophylaxis at a normal dose
  4. Total modified IMPROVE VTE Risk Score 4, or Total modified IMPROVE VTE Risk Score 2 or 3 and D-dimer >500 ng/ml



Important Findings:


At 35 days, the primary outcome, a composite of symptomatic VTE, VTE-related death, bilateral VTE, symptomatic arterial thromboembolism, myocardial infarction, non-hemorrhagic stroke, major adverse limb event, or cardiovascular death, was 3.14 percent in the rivaroxaban group versus 9.43 percent in the control group (p = 0.03).


The use of rivaroxaban for 35 days following a COVID-19 infection was found to be effective in individuals who were discharged. Rivaroxaban was linked to a decrease in clinical events without increasing severe hemorrhage.


This small trial found that taking rivaroxaban after being admitted to the hospital for COVID-19 reduced the composite of symptomatic venous thromboembolism (VTE), VTE-related death, bilateral VTE, symptomatic arterial thromboembolism, MI, non-hemorrhagic stroke, major adverse limb event, or cardiovascular death at 35 days without increasing bleeding.


Other trials have revealed that medically unwell (non-COVID 19) individuals who may continue to have limited mobility at home while convalescing may benefit from anticoagulation after discharge.

Comments

Post a Comment

Popular posts from this blog

EMPEROR-Preserved 2021 (Empagliflozin in HFpEF)

 Empagliflozin is better than placebo in improving HF outcomes among patients with symptomatic stable HFpEF on good baseline GDMT, regardless of diabetes status, according to the EMPEROR-Preserved study. The trial's purpose was to see if empagliflozin was safe and effective in patients with symptomatic heart failure with preserved ejection fraction (HFpEF), regardless of diabetes. Design of the Study: Patients were randomly assigned to either empagliflozin 10 mg (n = 2,997) or a placebo (n = 2,991) in a 1:1 ratio. Geographic location, diabetes status, estimated glomerular filtration rate (eGFR), and left ventricular ejection fraction were all used to stratify the experiment (LVEF: more or less than 50 percent ). All of the patients were being treated for heart failure. 11,583 people were screened in total. The total number of students enrolled is 5,988. Follow-up period: 26.2 months (median) The average patient is 72 years old. 45 percent of the population is female. The major outc...
Read more

MASTER DAPT Trial 2021

 In terms of net adverse clinical events, the MASTER DAPT trial found that shortened antiplatelet medication was not inferior to regular antiplatelet therapy. Description: The trial's purpose was to compare shortened antiplatelet therapy to standard antiplatelet therapy in patients who had percutaneous coronary intervention (PCI) using a biodegradable-polymer sirolimus-eluting stent. Design of the Study:  Participants with symptomatic coronary artery disease who had PCI during the previous 30-44 days were randomly assigned to one of two groups: shortened therapy (n = 2,295) or standard therapy (n = 2,284). Among people who do not require oral anticoagulation: Participants in the abbreviated therapy group promptly discontinued dual antiplatelet therapy (DAPT) and continued single antiplatelet therapy. Participants in the conventional therapy group received DAPT for 5 months before switching to mono antiplatelet medication. Those with an indication for oral anticoagulation inclu...
Read more

CRAVE Trial 2021 (Coffee Intake)

 The CRAVE trial found that coffee drinking increased PVCs and decreased sleep but decreased atrial arrhythmias and boosted physical activity. "These findings add to the emerging evidence that those with supraventricular tachycardia or atrial fibrillation should not avoid coffee," researchers said.  The research, conducted by Gregory M. Marcus, MD, MA, FACC, included 100 non-Hispanic White people with a median age of 38. Each participant wore an ECG monitor, a diabetes monitor, and a Fitbit. Researchers utilized a smartphone app to collect geolocation data and genotyped participants' DNA for coffee metabolism-related SNPs. Participants were randomly assigned to drink or avoid coffee for 14 days, with daily SMS reminders.  Overall, coffee intake was related with a 54% increase in PVCs, 36 minutes less sleep per night, and 1,058 more Fitbit-based steps per day. Each extra cup of coffee was linked to 3% more daily premature atrial contractions and 18 minutes less sleep. No s...
Read more